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schemia and reperfusion (IR) injury is a complex and multifactorial process that contributes to overall final infarct size after ST-elevation myocardial infarction. 1 Although rapid reperfusion and clinical treatment have led to significant improvements in survival after ST-elevation myocardial infarction, this approach has paradoxically contributed to an increase in patients with heart failure after myocardial infarction. 1 As the likelihood of developing heart failure is related to overall infarct size, it is important to identify novel treatments that can target IR injury. 2 The past 30 years have witnessed numerous insights into the multifarious processes of IR injury, and yet with each step forward, the Holy Grail of a clinically effective cardioprotective agent seems to recede further into the distance. For instance, it has been known since well before the millennium that a burst of reactive oxygen species (ROS) production occurs with the reintroduction of oxygen-rich blood to the ischemic myocardium on recanalization. 3 However, antioxidants have proven ineffective at limiting infarction. A further step forward was taken with the realization that not all ROS are necessarily damaging. However, mitochondria produce excess ROS during reperfusion, leading to opening of the mitochondrial permeability transition pore and mitochondrial damage. 4 Although mitochondria remain a viable target, attempts so far to target this mechanism have not been clinically successful.
The inflammatory response makes an important contribution to all stages of myocardial IR injury and is another major source of oxidative stress in the reperfused myocardium. Although neutrophils are the first responders to injury, they are swiftly followed by the undertakers (ie, macrophages), whose task is to remove apoptotic cells and debris. 5 In response to myocardial infarction, large numbers of monocytes emerge from the bone marrow and spleen and invade the damaged myocardium. The first, proinflammatory wave of M1-like macrophages peaks at days 3 to 4, whereas the second wave arrives after ≈1 week, differentiates into M2-like macrophages, and initiates repair and remodeling. However, it is important to realize that there are already numerous resident macrophages within the healthy heart, accounting for ≈10% of noncardiomyocytes. 6 The NADPH oxidases of the NOX family are major sources of ROS in cardiovascular disease. These oxidases include NOX1-3, which produce superoxide when activated, and NOX4, which is unique in that it is constitutively active and produces H 2 O 2 rather than superoxide. Mice lacking any of NOX1, NOX2, or NOX4 are protected from myocardial IR injury. 7 One of the major sources for NOX-derived ROS is neutrophils, but other inflammatory cell types, including macrophages and cardiomyocytes, contribute, as illustrated by the fact that isolated, perfused hearts lacking NOX1 or NOX2 are also protected against IR injury. are unlikely to contribute to early ROS generation in the heart because they do not infiltrate infarcted tissue before 8 to 12 hours. However, cardiac-resident macrophages, which are already present, may contribute to ROS generation in myocardial IR injury. The protein megakaryoblastic leukemia 1 (MKL1), also known as myocardin-related transcription factor A, couples cellular mechanical stress to nuclear transcription. Monomeric G-actin in the cytosol binds MKL1, but when this polymerizes into F-actin filaments, MKL1 is released to translocate to the nucleus, where it cooperates with the transcription factor serum response factor to modulate transcription (Figure) . 8 Despite its being widely expressed and abundant in the heart, wholebody deletion of Mkl1 has surprisingly little effect on normal mouse physiology, chiefly impairing mammary gland development and lactation. 8 However, physical stress, such as that triggered by cardiac pressure overload, activates an MKL1-dependent transcriptional response in cardiomyocytes, which protects them against dilated cardiomyopathy.
9 After myocardial infarction, MKL1 contributes to cardiac remodeling, regulating In resting myocardial macrophages, MKL1 is bound to cytosolic G-actin. Mechanical stress andGPCR-mediated activation of Rho leads to F-actin polymerization, thereby liberating MKL1 to migrate to the nucleus, where it recognizes and binds transcriptional regulatory sites, recruits the H4K16 acetyltransferase MOF, and increases the expression of the NADPH oxidases Nox1, Nox2, and Nox3, leading to increased oxidative stress and myocardial damage. GPCR indicates G-proteincoupled receptor; MKL1, megakaryoblastic leukemia 1; MOF, Male absent on the first; and MRTF-A, myocardin-related transcription factor A. myofibroblast activation and fibrosis. 10 However, the role of MKL1 in the early phase of IR injury was not previously established.
This issue of Circulation contains a detailed examination of the role of MKL1 in the myocardial response to IR injury. 11 Mice lacking MKL1 were protected against IR injury, manifesting smaller infarcts and better cardiac function measured by echocardiography after 45 minutes of coronary artery occlusion followed by 24 hours of reperfusion. 11 It is interesting to note that mice with macrophage-or cardiomyocyte-specific deletion of Mkl1 revealed that it is not the MKL1 in cardiomyocytes but rather the MKL1 in macrophages that is responsible for the increase in ROS and leads to IR injury in this experimental model. 11 A wide variety of in vitro and in vivo experiments was used to determine that MKL1 in cardiac macrophages induces the transcription of NOX1, NOX2, and NOX4 (but not NOX3). Using chromatin immunoprecipitation, hypoxia followed by reoxygenation was shown to increase MKL1 binding to the promoters of these Nox genes in macrophages.
11
MKL1 then recruits the H4K16 acetyltransferase Male absent on the first (MOF), which promotes accumulation of active histone acetylation marks, including panacetyl H3 (H3Ac), pan-acetyl H4 (H4Ac), and trimethylated H3K4 (H4K4Me3). 11 Thus, MKL1 appears to activate transcription of Nox1, Nox2, and Nox4 genes in macrophages by opening the chromatin structures of the promoters.
MOF was originally identified in fruit flies, where it was found to be essential to ensure appropriate expression of genes on the X chromosome, which are present in only 1 copy. However, in higher animals, it has multiple critical roles in regulating certain genes, including some of those involved in cellular stress. MOF expression is down-regulated in failing human hearts and hypertrophic murine hearts, and transgenic mice overexpressing MOF exhibit less oxidative stress and are protected from cardiac hypertrophy. 12 In addition to using cell-specific transgenic mice, the findings were corroborated using several different pharmacological inhibitors. These inhibitors included CCG-1423, an MKL1 inhibitor; and MG149, an MOF inhibitor. 11 Somewhat unexpectedly, daily administration for 3 days before infarction conferred only limited protection against infarct formation and provided no benefit in terms of contractile function. 11 This finding could be explained by Western blot analyses showing that nuclear accumulation of MKL1 and ROS production was only partially suppressed after 3 days. When pretreatment was extended to 14 days, MKL1 activation and ROS production were completely inhibited, and this resulted in more complete protection against IR injury.
Given that MKL1 appears to act via NADPH oxidase, one could ask, "Why not directly inhibit the NADPH oxidase?" Indeed, this experiment was also performed using the NOX1/NOX4-specific inhibitor GKT137831 via intragastric lavage for 2 weeks before the IR procedure; similar beneficial effects were observed. 11 Despite these encouraging results, it remains unclear whether the requirement for extended treatment was because of the doses of drugs being insufficient or is indicative of secondary changes that must occur to induce cardioprotection. It is also difficult to be certain that the benefit seen with the drugs was solely because of effects on macrophages and not on other cell types such as cardiomyocytes. In addition to fibroblasts, mentioned earlier, MKL1 plays important roles in neutrophils and the endothelium. 13, 14 The authors provide evidence that the drugs inhibited MOF in macrophages and not in cardiomyocytes, but it is not entirely clear why this should be the case. It would be informative to investigate whether mice with macrophage-restricted deletion of MKL1 demonstrate additional protection on administration of the drugs.
In any case, in combination with previous publications, data suggest that the MKL1/MOF pathway is a promising target for clinical treatment of myocardial infarction and cardiac remodeling. It is notable that no adverse effects were observed during 2 weeks of administration. If, as it seems, MKL1 is mainly involved in stress-specific responses and not in normal physiology, 8, 10, 11 then it may represent a tractable target. Of course outstanding questions remain. For example, how does IR activate MKL1? One possibility is direct mechanical stretch, but a receptor-Rho-mediated pathway could also be involved. Furthermore, as the authors rightly point out, their studies were limited to 24 hours of reperfusion, and it will be important to test for longer-term benefit of these drugs on cardiac remodeling. Last, returning to the topic of our introduction, a vital but challenging step will be the clinical translation of these observations to the patient. In this regard, it is increasingly recognized that the traditional one drug, one target approach has limited ability to protect against IR injury, which consists of many independent processes. 15 Instead, a multitarget approach 15 may be necessary for optimal clinical translation of cardioprotection. If this is indeed this case, then a drug inhibiting the MKL1-MOF pathway, which appears to have multiple molecular targets across several cell types in the heart, might just fit the bill. 
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